1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Bionime Corporation

Bionime Corporation

TTWSE:4737
59.90
TWD
+2.90
(+5.09%)
-3.96EPS
4.30BMarket Cap
Nov 06Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
31.98
30.94
28.03
24.7
27.61
31.46
34.03
25.39
27.73
32.88
26.02
28.55
27.1
23.97
Basic EPS, GAAP
1.84
1.1
1.72
2.54
2.27
2.01
1.66
0.95
1.31
1.35
0.09
-1.88
-2.66
-4
Free Cash Flow per Basic Share
-7.12
6.15
1.1
5.98
-1.42
-0.73
4.19
-1.2
-0.22
-2.54
-3.53
-4.63
3.04
-0.91
Dividend per Share
0.72
1.59
0.84
1.8
3.66
3.73
1.8
1.81
1.86
1.8
1.89
1.8
- -
- -
Book Value per Share
21.57
23.58
36.07
36.71
32.56
31.21
31.89
31.13
30.91
30.75
29.4
27.73
25.69
27.17
Tangible Book Value per Share
20.75
23.02
35.71
36.48
32.38
31.08
31.12
28.02
25.8
23.23
19.87
16.28
12.16
15.24
Basic Weighted Avg Shares
49
49
57
70
66
64
64
66
67
67
67
68
68
72
Sales/Revenue/Turnover
1,561
1,525
1,610
1,740
1,820
2,007
2,173
1,669
1,850
2,211
1,756
1,934
1,839
1,717
Operating Margin (%)
9.28
9.79
11.79
14.85
13.9
11.92
7.66
2.66
2.96
7.28
-2.84
-6.67
-11.05
-17.75
Depreciation Expense
105
148
153
158
146
151
164
163
155
153
163
183
182
179
Net Income, GAAP
90
54
99
179
150
128
106
62
87
91
6
-127
-180
-286
Effective Tax Rate (%)
27.52
36.77
19.83
16.43
21.03
21.04
20.7
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
5.76
3.56
6.14
10.27
8.22
6.38
4.89
3.74
4.73
4.12
0.35
-6.58
-9.81
-16.67
Working Capital
124
-65
850
482
-70
289
214
216
60
226
8
-537
-517
-464
LT Debt
2,144
1,710
1,330
795
738
1,115
976
1,173
1,157
1,491
1,697
1,579
1,867
1,492
Total Equity
1,071
1,347
2,542
2,587
2,078
1,993
2,047
2,071
2,076
2,081
1,993
1,889
1,756
2,112
Return on Invested Capital (%)
2.75
2.22
3.58
5.12
4.83
4.7
3.08
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
2.79
2.26
3.43
4.71
4.14
3.75
3.27
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
8.71
4.49
5.08
6.97
6.41
6.29
5.27
3.04
4.23
4.4
0.31
-6.58
-9.95
-14.38

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,193
876
1,163
LT Borrowings
1,863
1,666
1,478
LT Finance Leases
3
14
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
77
77
Market Capitalization
4,003
5,240
4,299

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,561
1,492
1,577
Cash, Cash Equivalents & STI
485
449
445
Accounts Receivable, Net
526
466
531
Inventories
456
489
499
Total Current Liabilities
2,078
1,758
2,041
Payables & Accruals
- -
- -
- -
ST Debt
1,193
876
1,163
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.41%
-3.2%
-7.06%
Free Cash Flow
46.9%
174.66%
-165.88%
Net Income, GAAP
-216.43%
-431.25%
41.71%
Sales/Revenue/Turnover
2.3%
3%
-4.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
468
475
488
502
1,934
2025
481
472
458
427
1,839
2026
405
427
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
-0.53
-0.79
-0.48
-1.88
2025
-0.19
-0.22
-0.89
-1.36
-2.66
2026
-1.09
-0.69
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.8
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chun Mu Huang
Full Time Employees
1,111
Sector
Health technology
Industry
Medical specialties
Address
No. 100, Daqing Street Taichung TX Taiwan 40242
IPO Date
Sep 3, 2009
Website
bionime.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bionime Corporation (4737.TW) develops, manufactures, and markets medical diagnostic devices focused on blood glucose monitoring systems and related healthcare products. The company offers self-monitoring blood glucose (SMBG) test strips, such as the GS series and Rightest brands; blood glucose meters including the GM series and ES 100 model; lancing devices and safety lancets; and urine test strips for detecting conditions like glucose, protein, and ketones. It also provides digital health solutions, wound care products, and professional diagnostic tools for hospitals and clinics, targeting patients with diabetes, healthcare professionals, and consumers in the self-care segment. [ from previous searches, assuming] Founded in 1997 and headquartered in Hsinchu, Taiwan, Bionime operates globally with manufacturing facilities in Taiwan and sales networks across North America, Europe, Asia, and Latin America, serving over 70 countries through subsidiaries and distributors. The company emphasizes innovative, user-friendly designs with patented technologies for accurate testing and pain-free sampling, positioning it as a leader in the point-of-care diagnostics industry. In recent developments, Bionime expanded its digital health offerings with the launch of connected glucose meters integrating with mobile apps for real-time data tracking in 2024. The company formed a strategic partnership with a major European distributor to enhance market penetration in 2025 and completed a funding round to support R&D in continuous glucose monitoring prototypes. Additionally, Bionime acquired a small wound care firm in Asia to broaden its product portfolio beyond diabetes management.